Which has higher earnings & valuation, KRRO or MDXG?

MiMedx Group has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 31.10 -$117.26M -$10.00 N/A MiMedx Group $418.63M 1.49 $48.58M $0.04 106.75

Is KRRO or MDXG more profitable?

MiMedx Group has a net margin of 1.76% compared to Korro Bio's net margin of -1,834.48%. MiMedx Group's return on equity of 12.09% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% MiMedx Group 1.76% 12.09% 9.22%

Does the media refer more to KRRO or MDXG?

In the previous week, Korro Bio had 5 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Korro Bio and 1 mentions for MiMedx Group. Korro Bio's average media sentiment score of 0.50 beat MiMedx Group's score of 0.46 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or KRRO more profitable?

Shattuck Labs has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Shattuck Labs' return on equity of -60.73% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Korro Bio -1,834.48% -114.26% -68.57%

Does the media favor STTK or KRRO?

In the previous week, Korro Bio had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Korro Bio and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Korro Bio's score of 0.50 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings and valuation, KRRO or ALT?

Altimmune has lower revenue, but higher earnings than Korro Bio. Altimmune is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 31.10 -$117.26M -$10.00 N/A Altimmune $40K 14,828.34 -$88.09M -$0.93 N/A

Is KRRO or ALT more profitable?

Korro Bio has a net margin of -1,834.48% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% Altimmune -214,860.98% -42.57% -35.57%

Does the media favor KRRO or ALT?

In the previous week, Korro Bio had 1 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Korro Bio and 5 mentions for Altimmune. Korro Bio's average media sentiment score of 0.50 beat Altimmune's score of 0.15 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, KRRO or ARVN?

Arvinas has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 31.10 -$117.26M -$10.00 N/A Arvinas $262.60M 2.21 -$80.80M $0.10 89.90

Is KRRO or ARVN more profitable?

Arvinas has a net margin of 2.94% compared to Korro Bio's net margin of -1,834.48%. Arvinas' return on equity of 1.91% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% Arvinas 2.94% 1.91% 1.29%

Does the media refer more to KRRO or ARVN?

In the previous week, Arvinas had 23 more articles in the media than Korro Bio. MarketBeat recorded 29 mentions for Arvinas and 6 mentions for Korro Bio. Arvinas' average media sentiment score of 0.52 beat Korro Bio's score of 0.50 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Arvinas 6 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts rate KRRO or VECT?

Korro Bio currently has a consensus price target of $16.71, suggesting a potential upside of 23.90%. Given Korro Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Korro Bio is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 2.92 VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, KRRO or VECT?

VectivBio has lower revenue, but higher earnings than Korro Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 31.10 -$117.26M -$10.00 N/A VectivBio N/A N/A N/A N/A N/A

Is KRRO or VECT more profitable?

VectivBio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. VectivBio's return on equity of 0.00% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% VectivBio N/A N/A N/A

Korro Bio (KRRO) Competitors

$13.49 +0.24 (+1.81%)

As of 04:00 PM Eastern

Compare

KRRO vs. MDXG, STTK, ALT, ARVN, and VECT

Should you buy Korro Bio stock or one of its competitors? Korro Bio's main competitors and comparable companies include MiMedx Group (MDXG), Shattuck Labs (STTK), Altimmune (ALT), Arvinas (ARVN), and VectivBio (VECT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Korro Bio compare to MiMedx Group?

Korro Bio (NASDAQ:KRRO) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A
MiMedx Group	$418.63M	1.49	$48.58M	$0.04	106.75

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 23.90%. MiMedx Group has a consensus target price of $8.50, suggesting a potential upside of 99.06%. Given MiMedx Group's higher possible upside, analysts plainly believe MiMedx Group is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Korro Bio had 5 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Korro Bio and 1 mentions for MiMedx Group. Korro Bio's average media sentiment score of 0.50 beat MiMedx Group's score of 0.46 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Korro Bio has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

MiMedx Group has a net margin of 1.76% compared to Korro Bio's net margin of -1,834.48%. MiMedx Group's return on equity of 12.09% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
MiMedx Group	1.76%	12.09%	9.22%

Summary

MiMedx Group beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Shattuck Labs has higher earnings, but lower revenue than Korro Bio. Shattuck Labs is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	547.50	-$48.81M	-$0.63	N/A
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A

In the previous week, Korro Bio had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Korro Bio and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.90 beat Korro Bio's score of 0.50 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Shattuck Labs has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Shattuck Labs' return on equity of -60.73% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Korro Bio	-1,834.48%	-114.26%	-68.57%

Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market.

Shattuck Labs presently has a consensus price target of $12.63, suggesting a potential upside of 76.82%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 23.90%. Given Shattuck Labs' higher probable upside, equities research analysts plainly believe Shattuck Labs is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats Korro Bio on 11 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Altimmune?

Korro Bio (NASDAQ:KRRO) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Korro Bio has a net margin of -1,834.48% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
Altimmune	-214,860.98%	-42.57%	-35.57%

Korro Bio currently has a consensus price target of $16.71, indicating a potential upside of 23.90%. Altimmune has a consensus price target of $15.71, indicating a potential upside of 415.22%. Given Altimmune's higher probable upside, analysts plainly believe Altimmune is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Altimmune has lower revenue, but higher earnings than Korro Bio. Altimmune is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A
Altimmune	$40K	14,828.34	-$88.09M	-$0.93	N/A

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Korro Bio has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Korro Bio had 1 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Korro Bio and 5 mentions for Altimmune. Korro Bio's average media sentiment score of 0.50 beat Altimmune's score of 0.15 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Korro Bio beats Altimmune on 9 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Arvinas?

Korro Bio (NASDAQ:KRRO) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Korro Bio has a beta of 3.04, suggesting that its share price is 204% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arvinas has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A
Arvinas	$262.60M	2.21	-$80.80M	$0.10	89.90

In the previous week, Arvinas had 23 more articles in the media than Korro Bio. MarketBeat recorded 29 mentions for Arvinas and 6 mentions for Korro Bio. Arvinas' average media sentiment score of 0.52 beat Korro Bio's score of 0.50 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Arvinas	6 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Korro Bio presently has a consensus target price of $16.71, suggesting a potential upside of 23.90%. Arvinas has a consensus target price of $14.17, suggesting a potential upside of 57.58%. Given Arvinas' higher probable upside, analysts clearly believe Arvinas is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Arvinas has a net margin of 2.94% compared to Korro Bio's net margin of -1,834.48%. Arvinas' return on equity of 1.91% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
Arvinas	2.94%	1.91%	1.29%

Summary

Arvinas beats Korro Bio on 12 of the 17 factors compared between the two stocks.

How does Korro Bio compare to VectivBio?

Korro Bio (NASDAQ:KRRO) and VectivBio (NASDAQ:VECT) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

VectivBio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. VectivBio's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
VectivBio	N/A	N/A	N/A

VectivBio has lower revenue, but higher earnings than Korro Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A
VectivBio	N/A	N/A	N/A	N/A	N/A

Korro Bio currently has a consensus price target of $16.71, suggesting a potential upside of 23.90%. Given Korro Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Korro Bio is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

13.2% of Korro Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Korro Bio had 6 more articles in the media than VectivBio. MarketBeat recorded 6 mentions for Korro Bio and 0 mentions for VectivBio. Korro Bio's average media sentiment score of 0.50 beat VectivBio's score of 0.00 indicating that Korro Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Korro Bio	Positive
VectivBio	Neutral

Summary

Korro Bio beats VectivBio on 8 of the 12 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$195.12M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.35	5.30	210.34	20.96
Price / Sales	31.10	1,255.26	588.78	86.31
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	2.47	17.66	11.27	6.42
Net Income	-$117.26M	-$13.25M	$3.45B	$347.03M
7 Day Performance	25.61%	5.36%	3.56%	2.48%
1 Month Performance	-7.35%	-1.74%	-0.58%	-1.04%
1 Year Performance	-15.69%	61.36%	77.52%	23.22%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.7975 of 5 stars	$13.49 +1.8%	$16.71 +23.9%	-17.2%	$195.12M	$6.39M	N/A	70	Earnings Report Analyst Upgrade
MDXG MiMedx Group	2.8 of 5 stars	$4.27 flat	$8.50 +99.1%	-38.2%	$622.40M	$418.63M	106.78	870
STTK Shattuck Labs	3.099 of 5 stars	$7.92 +8.6%	$12.63 +59.4%	+861.3%	$607.31M	$1M	N/A	100	Upcoming Earnings
ALT Altimmune	2.0975 of 5 stars	$3.07 +2.3%	$15.71 +411.9%	-10.7%	$597.02M	$40K	N/A	50	Upcoming Earnings
ARVN Arvinas	3.448 of 5 stars	$9.00 +11.7%	$15.08 +67.6%	+39.1%	$580.68M	$262.60M	N/A	420	Earnings Report Analyst Upgrade Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. MDXG, STTK, ALT, ARVN, and VECT

How does Korro Bio compare to MiMedx Group?

Summary

How does Korro Bio compare to Shattuck Labs?

Summary

How does Korro Bio compare to Altimmune?

Summary

How does Korro Bio compare to Arvinas?

Summary

How does Korro Bio compare to VectivBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. MDXG, STTK, ALT, ARVN, and VECT

How does Korro Bio compare to MiMedx Group?

Do insiders and institutionals have more ownership in KRRO or MDXG?

Which has higher earnings & valuation, KRRO or MDXG?

Do analysts rate KRRO or MDXG?

Does the media refer more to KRRO or MDXG?

Which has more volatility & risk, KRRO or MDXG?

Is KRRO or MDXG more profitable?

Summary

How does Korro Bio compare to Shattuck Labs?

Which has better earnings and valuation, STTK or KRRO?

Does the media favor STTK or KRRO?

Is STTK or KRRO more profitable?

Which has more risk and volatility, STTK or KRRO?

Do analysts rate STTK or KRRO?

Do institutionals & insiders hold more shares of STTK or KRRO?

Summary

How does Korro Bio compare to Altimmune?

Is KRRO or ALT more profitable?

Do analysts recommend KRRO or ALT?

Which has preferable earnings and valuation, KRRO or ALT?

Do insiders and institutionals have more ownership in KRRO or ALT?

Which has more risk & volatility, KRRO or ALT?

Does the media favor KRRO or ALT?

Summary

How does Korro Bio compare to Arvinas?

Which has more risk & volatility, KRRO or ARVN?

Do insiders & institutionals believe in KRRO or ARVN?

Which has better earnings & valuation, KRRO or ARVN?

Does the media refer more to KRRO or ARVN?

Do analysts prefer KRRO or ARVN?

Is KRRO or ARVN more profitable?

Summary

How does Korro Bio compare to VectivBio?

Is KRRO or VECT more profitable?

Which has preferable valuation & earnings, KRRO or VECT?

Do analysts rate KRRO or VECT?

Do insiders and institutionals believe in KRRO or VECT?

Does the media favor KRRO or VECT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools